This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

ATX-101 Abdominoplasty (ATX-101-08-10)

This study has been completed.
Information provided by:
Kythera Biopharmaceuticals Identifier:
First received: February 3, 2009
Last updated: January 25, 2010
Last verified: January 2010
Histopathological study of abdominal fat excised from subjects undergoing abdominoplasty

Condition Intervention Phase
Characteristics of Subcutaneous Fat Drug: ATX-101 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Phase 1, Open-label Study of the Safety, Tolerability, and Histological Effect of Single Doses of ATX-101 (Sodium Deoxycholate for Injection) Administered in Abdominal Fat in Subjects Undergoing Abdominoplasty

Further study details as provided by Kythera Biopharmaceuticals:

Primary Outcome Measures:
  • Adverse events, laboratory test results, physical examinations [ Time Frame: 1 - 28 days ]

Secondary Outcome Measures:
  • Histopathology [ Time Frame: 1 - 28 Days ]

Estimated Enrollment: 14
Study Start Date: November 2008
Study Completion Date: April 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ATX-101 Drug: ATX-101
ATX-101 single doses


Ages Eligible for Study:   25 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy subjects undergoing planned abdominoplasty

Exclusion Criteria:

  • History of interventions in the abdominal area
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00835952

United States, California
San Francisco, California, United States
Santa Monica, California, United States
Sponsors and Collaborators
Kythera Biopharmaceuticals
Study Director: Patricia Walker, M.D., Ph.D. Kythera Biopharmaceuticals, Inc.
  More Information

Responsible Party: Director, Clinical Affairs, Kythera Biopharmaceuticals, Inc. Identifier: NCT00835952     History of Changes
Other Study ID Numbers: ATX-101-08-10
Study First Received: February 3, 2009
Last Updated: January 25, 2010 processed this record on August 18, 2017